Vivisection In Animal Testing

1254 Words3 Pages

Animal testing is defined as the use of non-human animals in tests and experiments (Wikipedia, 2014). Whether the experimentation encompasses actual tests that affect certain aspects of the animals or it encompasses simply the observation of an animal’s behavior, it is classified as animal testing. Animal testing can often be conducted in numerous locations, such as a university, medical schools, pharmaceutical companies, farms, defense facilities, and commercial establishments that utilize animal testing for commerce such as a cosmetic company (Wikipedia, 2014). Tests that animals have been involved in include toxicology tests, cosmetic tests, behavioral studies, and developmental biology. In total, there is an estimated to be about 100 million animals used annually during animal treating and it is estimated that about 80 million animals were used in the US alone in 2001(Wikipedia, 2014). After being used in various experimentations, animals are euthanized (Wikipedia, 2014).
Humans have made use of animals as models for anatomy and physiology since the beginning of medicine. It was recorded that ancient Grecians dissected animals for certain anatomical studies (Franco, 2013). The dissection of the animals was and is called vivisection. The term vivisection can be viewed as the definition of animal testing for medical research since it is the practice of performing operations on living animals for experimentation and research (Franco, 2013). Some of the earliest physicians to perform vivisections include Alcmaeon during the 6th and 5th century BCE, Aristotle, Diocles and Praxagoras during the 4th century BCE, Erasistratus and Herophilus during the 3rd century BCE (Franco, 2013). Initially, Grecians did not believe that us...

... middle of paper ...

...ed on during clinical trials for drugs prior to their market rather than using an animal as it (Kehinde, 2013). The counterargument for this stated that the difficulties that would be encountered with this method primarily stem from the wide and various side effects that could appear after the product has been marketed (Kehinde, 2013).
This is because most initial clinical trials of a new drug in humans would typically require testing the new drug on about 3,000 human volunteers and patients. Consequently, if a side effect occurs in 1 in 10,000 patients, such side effects may not become apparent until after the product has been marketed. Furthermore, human clinical trials often involve a relatively homogeneous sample of patients in order to distinguish clearly between the effects of the therapy against the background of variation between different patient responses

Open Document